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The Ineffectiveness of Retrospective Drug Utilization Review
Abstract
As policymakers debate adding a prescription drug benefit to Medicare, they must also seek ways to promote
cost-effective use of drugs and minimize inappropriate prescribing. For more than a decade, all state Medicaid
agencies and most private insurers have used computerized drug utilization review (DUR) programs to
prevent or rectify potential prescribing errors. DUR can be retrospective, in which claims data are reviewed to
identify patterns of drug use, or prospective, in which prescriptions are reviewed before a drug is dispensed.
This Issue Brief summarizes a landmark study that suggests that retrospective DUR has had no measurable
effects on outpatient drug use or clinical outcomes in the Medicaid program.
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The Ineffectiveness of Retrospective
Drug Utilization Review
Editor’s note:  As policymakers debate adding a prescription drug benefit to
Medicare, they must also seek ways to promote cost-effective use of drugs and
minimize inappropriate prescribing.  For more than a decade, all state Medicaid
agencies and most private insurers have used computerized drug utilization review
(DUR) programs to prevent or rectify potential prescribing errors.  DUR can be
retrospective, in which claims data are reviewed to identify patterns of drug use, or
prospective, in which prescriptions are reviewed before a drug is dispensed.  This
Issue Brief summarizes a landmark study that suggests that retrospective DUR has
had no measurable effects on outpatient drug use or clinical outcomes in the
Medicaid program.
In 1990, Congress required all state Medicaid agencies to implement DUR
programs by 1993.  The legislative goal was to assure that outpatient
prescriptions were appropriate, medically necessary, and unlikely to have
adverse medical consequences.  One component of the mandated program is
retrospective DUR, in which claims are reviewed to identify prescribing
problems or errors.  Software is used to identify problems such as drug-drug
interactions, overuse (for example, early refills), drug-disease interactions,
duplicate therapy, excessive or insufficient dose, and drug pregnancy
contraindications.
• A typical retrospective DUR process involves computerized screening of
drug claims each month to detect “exceptions” that appear to violate
predetermined criteria for appropriate prescribing.  If the criteria are valid,
then exceptions represent prescribing errors.  For example, one criterion is
that a given patient should not receive more than one narcotic analgesic at
one time.
• Exceptions are reviewed manually to determine whether a physician alert
should be issued.  Alerts are typically made through the mail, although a
few programs do so by telephone.  Typical alert letters include the patient’s
name, the criterion that has been violated (sometimes with a reference
supporting the validity of the criterion), and a statement that the clinical
care of the patient remains at the discretion of the physician.
Study evaluates
retrospective DUR in
Medicaid programs in
six states
Retrospective DUR has
no effect on rates of
exceptions
• In theory, retrospective DUR programs might work through two
mechanisms: direct effects and spillover effects.  Direct effects apply to
patients who are identified in alerts and benefit from a change in therapy.
Spillover effects refer to the possibility that prescribers might apply lessons
learned from receiving an alert about one patient to the care of other
patients in the future.
• In practice, however, it is not clear that these retrospective DUR programs
work.  Despite a decade of implementation of retrospective DUR in all
Medicaid programs and in most private sector drug benefit programs, the
effectiveness of this mechanism has not been evaluated.
Hennessy and colleagues used data from six Medicaid programs over four
years to assess the direct effects of retrospective DUR on clinical outcomes in
patients with exceptions, and to assess changes in the rate of exceptions over
time, as might be expected if there were spillover effects.  Exceptions prior to
DUR implementation were identified using archived claims data and the
same algorithms currently used.
• The study sample included states from the four geographic regions of the
U.S., and both large and small Medicaid programs. These states used the
same DUR software vendor.  The analysis was limited to criteria that
identified drug-disease, drug-drug, and duplication problems because these
criteria account for about 80% of alerts issued.
• For each state, the investigators calculated the rate of exceptions per
thousand prescriptions.  The primary analysis assumed a two-month lag
between implementation and effects, although lags of one month and four
months were also considered.
• Clinical outcomes were measured by all-cause hospitalization rates, and
cause-specific hospitalizations following specific exceptions (for example,
hospitalizations for upper gastrointestinal bleeding after exceptions to
gastrointestinal criteria).  The primary observation period after each
exception was 120 days, although analyses were also performed using
periods of 90 and 150 days.
• The study included patients for whom an exception was issued, regardless
of whether an alert was sent.  This was done to permit identification of a
valid comparison group for before-after comparisons, because the process
of flagging exceptions for alerts is done using individual judgment and
implicit criteria, and therefore is not reproducible
Changes in the rate of exceptions, which represent potential prescribing
problems, were calculated before and after implementation of retrospective
DUR.
Continued on back.
Retrospective DUR has
no effect on clinical
outcomes in patients
with exceptions
POLICY IMPLICATIONS
• The average rate of exceptions was similar among states, ranging from 8 to
13 exceptions per 1000 prescriptions.
• Between 1% and 25% of exceptions identified with the software resulted
in an alert.  Each year, the programs issued 761 to 3236 alerts.
• Smaller states showed the highest alert rates.  The alert rate per state was
not associated with changes in the exception rate coincident with
retrospective DUR implementation.
• After adjusting for prior trends in drug use, the investigators found no
significant changes in the rate of exceptions associated with
implementation of retrospective DUR.  No effect on exceptions was
evident when considering a 1-month, 2-month or 4-month lag time
between DUR implementation and any effects.
The rate of hospitalizations in patients with exceptions was measured before
and after DUR implementation to ascertain any direct clinical benefit
attributable to the program.  The investigators also examined whether
retrospective DUR might have an effect primarily on exceptions based on
criteria that resulted in the highest number of physician alerts.
• The incidence of hospitalization of patients within 120 days of an
exception was virtually identical before and after implementation of
retrospective DUR (22% vs. 23%).  After adjusting for potential
individual-level factors, retrospective DUR had no effect on
hospitalizations in the 90, 120 or 150 days after the exception.
• Retrospective DUR had no effect on hospitalizations in the subgroup of
patients identified by the top five criteria that produced the highest
number of physician alerts. Although no direct before and after
comparison of patients with alerts was possible, this suggests that
retrospective DUR did not affect hospitalizations even in the group where
one might expect to find the largest effect.
• Even when the analysis was limited to specific exceptions thought to be
related to specific causes for hospitalizations (such as upper gastrointestinal
bleeding, myocardial infarction or angina), no effect of retrospective DUR
was detected.
This study included millions of Medicaid patients in six states that paid for
about 63 million prescriptions each study year, and identified more than
600,000 exceptions by retrospective DUR each year.  The study methods
adjusted for secular and time trends in drug use, and produced results
consistent across states, exception categories, and types of patients.
Retrospective DUR appears to have no measurable effects on prescribing
errors or clinical outcomes in the Medicaid program.
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POLICY IMPLICATIONS
Continued
• Given the lack of evidence for the effectiveness of retrospective DUR,
policymakers should consider withdrawing the legislative mandate for such
review in the Medicaid program.
• As legislators discuss a new drug benefit in the Medicare program, they
should not include requirements for retrospective DUR as it is currently
implemented in Medicaid.  It is possible that future DUR programs can be
improved to confer clinical benefits, but efforts to improve prescribing
should be shown to be effective before being widely adopted.
• The reasons for the apparent lack of effect of retrospective DUR need
exploration.  These reasons might include the unknown validity of many
criteria, the low alert rate, the time lag from the exception to the alert, and
the modest effectiveness of alert letters in changing prescribing, particularly
when letters are not based on any underlying reasons physicians might
have had for prescribing the medication.
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